Phenotypes associated with this allele

• Allele Symbol: Fntb^tm1.1Bbd
• Allele Name: targeted mutation 1.1, Mariano Barbacid
• Allele ID: MGI:3581448
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Fntb^tm1.1Bbd/Fntb^tm1.1Bbd	involves: 129S1/Sv * 129X1/SvJ * CD-1	MGI:3582833
cn2	Fntb^tm1Bbd/Fntb^tm1.1Bbd Polr2a^tm1(cre/ERT2)Bbd/Polr2a^tm1(cre/ERT2)Bbd	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL	MGI:3582821

Genotype
MGI:3582833

hm1

• Allelic Composition: Fntb^tm1.1Bbd/Fntb^tm1.1Bbd
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * CD-1

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:98944 )

• no homozygous embryos are found from E11.5 on

embryo

decreased inner cell mass proliferation ( J:98944 )

• after 4 days in culture the ICM of embryos collected at E3.5 displays a dramatic decrease in cell proliferation; however, trophoblast cells continue to proliferate

abnormal ectoderm development ( J:98944 )

• at E7.5 cell layers derived from the epiblast are absent, while structures derived from the ectoplacental cone and trophoblast giant cells are present

• loss of epiblast-derived structures appears to result from decreased cell proliferation

cellular

decreased inner cell mass proliferation ( J:98944 )

• after 4 days in culture the ICM of embryos collected at E3.5 displays a dramatic decrease in cell proliferation; however, trophoblast cells continue to proliferate

Genotype
MGI:3582821

cn2

• Allelic Composition: Fntb^tm1Bbd/Fntb^tm1.1Bbd; Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd}
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL

cellular

decreased cell proliferation ( J:98944 )

• double homozygous MEFs treated with 4-hydroxy-tamoxifen to induce Cre mediated recombination proliferate less efficiently compared to untreated double homozygous MEFs

hematopoietic system

small spleen ( J:98944 )

• about a 20% decrease in spleen size is seen in 6 month old double homozygous treated with 4-hydroxy-tamoxifen at 10 days of age

abnormal hematopoietic system physiology ( J:98944 )

• removal of 0.8 ml of blood from 6 month old double homozygous treated with 4-hydroxy-tamoxifen at 10 days of age resulted in a smaller increase in spleen size and in the splenic erythroid compartment compared to controls

immune system

small spleen ( J:98944 )

• about a 20% decrease in spleen size is seen in 6 month old double homozygous treated with 4-hydroxy-tamoxifen at 10 days of age

neoplasm

decreased incidence of tumors by chemical induction ( J:98944 )

• treatment with 4-hydroxy-tamoxifen 2 weeks after treatment with 7,12 dimethyl-benzanthracene (DMBA) and 12-o-tetradecanoylphorbol-13-acetate (TPA) results in fewer and smaller papillomas compared to mice that were mot treated with 4-hydroxy-tamoxifen

• however, treatment with 4-hydroxy-tamoxifen for 20 weeks before treatment with DMBA and TPA had no effect on tumor incidence, size, or pathological appearance compared to mice that were not treated with 4-hydroxy-tamoxifen

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:98944 )

• treatment with 4-hydroxy-tamoxifen 2 weeks after treatment with 7,12 dimethyl-benzanthracene (DMBA) and 12-o-tetradecanoylphorbol-13-acetate (TPA) results in fewer and smaller papillomas compared to mice that were mot treated with 4-hydroxy-tamoxifen

• however, treatment with 4-hydroxy-tamoxifen for 20 weeks before treatment with DMBA and TPA had no effect on tumor incidence, size, or pathological appearance compared to mice that were not treated with 4-hydroxy-tamoxifen

delayed wound healing ( J:98944 )

• 6 month old double homozygous treated with 4-hydroxy-tamoxifen at 10 days of age take 12 days to fully heal compared to 9 days for control mice; however at 10 weeks of age no difference was seen in wound healing or liver regeneration after partial hepatectomy (not done in 6 month old mice)